Statement: One patient in the primary trial suffered from an inflammation of the liver.
Primary_evidence: Adverse Events 1:   Total: 15/48 (31.25%)   Anemia * 1/48 (2.08%)   Cardiac failure congestive * 1/48 (2.08%)   Constipation * 2/48 (4.17%)   Esophagitis * 1/48 (2.08%)   Gastrointestinal hemorrhage * 1/48 (2.08%)   Non-Cardiac chest pain * 1/48 (2.08%)   Pain * 1/48 (2.08%)   Cholecystitis * 1/48 (2.08%)   Diverticulitis * 1/48 (2.08%)   Cellulitis * 1/48 (2.08%)   Gastroenteritis * 1/48 (2.08%)